Cardura Tablet, Film Coated, Extended Release
Product Images NDC 58151-079

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cardura (NDC 58151-079). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cardura Xl Extended Release Tablets 4 mg Bottle Label (Image 01)

Label for Cardura XL 4 mg extended-release tablets containing doxazosin mesylate. The label indicates 30 tablets per bottle, prescription use only, and is distributed by Viatris Specialty LLC. Storage instructions specify maintaining 25°C with permitted excursions and protection from moisture and humidity.*

FDA Label Image

Cardura Xl Extended Release Tablets 8 mg Bottle Label (Image 02)

Label for Cardura XL (doxazosin) extended-release tablets, 8 mg strength. The oral film-coated tablets come in a 30-count package. The label includes storage instructions at 25°C with excursions permitted between 15-30°C, a note on tablet composition, and prescribing information directions. Distributed by Viatris Specialty LLC.*

FDA Label Image

Doxazosin Mesylate Structural Formula (Image 03)

Chemical structure of doxazosin mesylate, showing the molecular arrangement of atoms including aromatic rings, amine groups, and methanesulfonic acid (mesylate) component.*

FDA Label Image

Figure 1: Mean (+sd) Plasma Concentration Of Doxazosin Following Single Oral Doses Of 8 mg Cardura Xl (fed And Fasted) (Image 04)

A line graph displaying plasma concentration (ng/mL) over time post dose (hours) for 8 mg Cardura XL tablets under fasted and fed conditions. The graph includes error bars to show variability and shows concentration peaking between 8 to 12 hours before declining.*

FDA Label Image

Figure 2: Mean Total Ipss (± Se) By Week In Study 1 (Image 05)

Line graph comparing mean total IPSS scores over weeks of treatment between Cardura XL and placebo groups. The x-axis represents weeks of treatment (0 to 15), and the y-axis shows mean total IPSS score (9 to 21). Data points show decreasing scores over time, with Cardura XL consistently lower than placebo, indicating symptom improvement.*

FDA Label Image

Figure 3: Mean Maximum Urinary Flow Rate (ml/sec) (± Se) By Week In Study 1 (Image 06)

A line graph depicting the mean maximum urinary flow rate (mL/sec) over weeks of treatment for Cardura XL compared to placebo. The x-axis shows weeks of treatment ranging from 0 to 15, and the y-axis shows urinary flow rate from 0 to 16 mL/sec. Data points with error bars illustrate trends in urinary flow rates for both groups over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.